AVENUE THERAPEUTICS INC (ATXI) 1.32 -0.06 (-4.35%)
1.32 -0.06 (-4.35%)
US05360L3042 - Common Stock - After market: 1.34 +0.02 (+1.52%)
Fundamental Rating
Taking everything into account, ATXI scores 1 out of 10 in our fundamental rating. ATXI was compared to 259 industry peers in the Pharmaceuticals industry. ATXI has a bad profitability rating. Also its financial health evaluation is rather negative. ATXI is valued expensive and it does not seem to be growing.
Note: ATXI has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
The Piotroski-F score of ATXI is 4.00. This is a neutral score and indicates average health and profitability for ATXI.
VS Industry
Valuation
Valuation Rating
The Price/Earnings Ratio is negative for ATXI. In the last year negative earnings were reported.
VS Industry
Growth
Growth Rating
ATXI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -107.47%.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -107.47% | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Health
Health Rating
ATXI has a Piotroski-F score of 4.00. This indicates an average health and profitability for ATXI.
ATXI has a Current Ratio of 0.94. This is a bad value and indicates that ATXI is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Current Ratio of ATXI to the average industry Current Ratio of 3.51, ATXI is less able to pay its short term obligations than its industry peers. 89% of its industry peers have a better Current Ratio.
ATXI has a Quick Ratio of 0.94. This is a bad value and indicates that ATXI is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Quick Ratio of ATXI to the average industry Current Ratio of 2.88, ATXI is less able to pay its short term obligations than its industry peers. 82% of its industry peers have a better Quick Ratio.
Based on the Altman-Z score of -220.12, we must say that ATXI is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.52, ATXI is in worse financial state than most of its industry peers. 100% of its industry peers have a better Altman-Z score.
VS Industry
Quick Ratio (0.94) VS Industry: 18% outperformed.
-2.73
76.82
Current Ratio (0.94) VS Industry: 11% outperformed.
0.10
76.82
Altman-Z (-220.12) VS Industry: 0% outperformed.
-229.49
88.63
Dividend
Dividend Rating
No dividends for ATXI!.
AVENUE THERAPEUTICS INC1.32
NASDAQ:ATXI (1/30/2023, 7:00:00 PM)-0.06 (-4.35%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Pharmaceuticals | ||
| Earnings (Last) | 11-10 2022-11-10/amc | Earnings (Next) | N/A N/A |
| Inst Owners | 0% | Inst Owner Change | 0% |
| Ins Owners | 11.76% | Ins Owner Change | -11.87% |
| Market Cap | 6.30M | Analysts | 43.33 |
| Price Target | N/A | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS beat(2) | N/A | Avg EPS beat(2) | N/A |
| Min EPS beat(2) | N/A | Max EPS beat(2) | N/A |
| EPS beat(4) | N/A | Avg EPS beat(4) | N/A |
| Min EPS beat(4) | N/A | Max EPS beat(4) | N/A |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | N/A |
| Min Revenue beat(2) | N/A | Max Revenue beat(2) | N/A |
| Revenue beat(4) | N/A | Avg Revenue beat(4) | N/A |
| Min Revenue beat(4) | N/A | Max Revenue beat(4) | N/A |
| PT rev (1m) | N/A | EPS NQ rev (1m) | N/A |
| EPS NY rev (1m) | N/A | Revenue NQ rev (1m) | N/A |
| Revenue NY rev (1m) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| EPS(TTM) | -3.66 | EY | N/A |
| EPS(NY) | N/A | Fwd EY | N/A |
| FCF(TTM) | -0.97 | FCFY | N/A |
| OCF(TTM) | -0.97 | OCFY | N/A |
| SpS | N/A | BVpS | -0.01 |
| TBVpS | -0.01 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | N/A | GM growth 5Y | N/A |
| F-Score | 4 | Asset Turnover | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | -220.12 |
| F-Score | 4 | WACC | N/A |
| ROIC/WACC | N/A | Cap/Depr(3y) | N/A |
| Cap/Depr(5y) | N/A | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | -107.47% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 40% |
| EPS Next Y | N/A | EPS Next 2Y | N/A |
| EPS Next 3Y | N/A | EPS Next 5Y | N/A |
| Revenue growth 1Y | N/A | Revenue growth 3Y | N/A |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | N/A |
| Revenue Next Year | N/A | Revenue Next 2Y | N/A |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| EBIT growth 1Y | -31.96% | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | N/A |
| EBIT Next 3Y | N/A | EBIT Next 5Y | N/A |
| FCF growth 1Y | 45.01% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | 45.01% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA